Lupin’s Japanese subsidiary - Kyowa Pharmaceutical Industry Company, has entered into a strategic asset purchase agreement with Shionogi & Company to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa.
As a part of this growth strategy, Shionogi would transfer 21 long-listed products to Kyowa, the Japanese subsidiary of Lupin. Kyowa is amongst the top 10 Generic companies in Japan and a market leader in Central Nervous System (CNS) space well known for its ‘AMEL’ brand, in addition to other generic pharmaceutical products in its portfolio. With this acquisition, Kyowa will rank sixth amongst generic companies in Japan.
The 21 products cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Antiinfectives. These 21 products had sales of JPY 9,400 million ($90 million) collectively on National Health Insurance (NHI) price basis.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.10 |
| Dr. Reddys Lab | 1289.65 |
| Cipla | 1309.00 |
| Zydus Lifesciences | 954.70 |
| Lupin | 2281.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: